[go: up one dir, main page]

KR20080111790A - Wrinkle improvement cosmetic composition - Google Patents

Wrinkle improvement cosmetic composition Download PDF

Info

Publication number
KR20080111790A
KR20080111790A KR1020070060177A KR20070060177A KR20080111790A KR 20080111790 A KR20080111790 A KR 20080111790A KR 1020070060177 A KR1020070060177 A KR 1020070060177A KR 20070060177 A KR20070060177 A KR 20070060177A KR 20080111790 A KR20080111790 A KR 20080111790A
Authority
KR
South Korea
Prior art keywords
cosmetic composition
cream
improving skin
collagen
skin wrinkles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1020070060177A
Other languages
Korean (ko)
Other versions
KR101416993B1 (en
Inventor
황재관
심재석
이해지
조유미
권송희
Original Assignee
(주)바이오케어
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)바이오케어 filed Critical (주)바이오케어
Priority to KR1020070060177A priority Critical patent/KR101416993B1/en
Priority to PCT/KR2008/003522 priority patent/WO2008156330A1/en
Priority to JP2010513123A priority patent/JP2010530412A/en
Publication of KR20080111790A publication Critical patent/KR20080111790A/en
Application granted granted Critical
Publication of KR101416993B1 publication Critical patent/KR101416993B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 통상의 화장료에 커큐마 잔토리자(Curcuma xanthorrhiza) 추출물로부터 분리된 하기 화학식 1의 잔토리졸(xanthorrhizol)을 함유시킴으로서 광노화에 의한 주름개선 효과를 갖는 화장료 조성물에 관한 것으로 본 발명의 주름개선 화장료 조성물은 콜라겐 분해효소-1(MMP-1, matrix metalloproteinase-1) 억제능력과 신생 콜라겐(type-1 procollagen) 합성 능력을 가지는 잔토리졸을 유효성분으로 함유하는 것을 특징으로 한다. 본 발명의 잔토리졸을 유효성분으로 함유하는 화장료 조성물은 광노화에 의한 주름형성의 치료 또는 예방에 매우 유용하게 사용될 수 있다.The present invention relates to a cosmetic composition having an anti-wrinkle effect by photoaging by containing xanthorrhizol represented by the following Chemical Formula 1, which is isolated from a Curcuma xanthorrhiza extract, in a conventional cosmetic. The improved cosmetic composition is characterized in that it contains xantolizol having the ability to inhibit collagen degrading enzyme-1 (MMP-1, matrix metalloproteinase-1) and the ability to synthesize new collagen (type-1 procollagen) as an active ingredient. The cosmetic composition containing the xantholizole of the present invention as an active ingredient can be very useful for the treatment or prevention of wrinkle formation by photoaging.

[화학식 1][Formula 1]

Figure 112007044421219-PAT00001
Figure 112007044421219-PAT00001

Description

주름개선용 화장료 조성물{Anti-wrinkle cosmetic composition}Anti-wrinkle cosmetic composition

도 1은 본 발명의 커큐마 잔토리자(Curcuma xanthorrhiza) 추출물에 의한 콜라겐 분해효소-1 억제활성을 나타낸 그래프이다. 1 is a graph showing collagen degrading enzyme-1 inhibitory activity by Curcuma xanthorrhiza extract of the present invention.

도 2는 본 발명의 커큐마 잔토리자(Curcuma xanthorrhiza) 추출물에 의한 콜라겐 합성능을 나타낸 그래프이다. 2 is a graph showing collagen synthesis ability by the Curcuma xanthorrhiza extract of the present invention.

도 3은 본 발명의 잔토리졸(xanthorrhizol)에 의한 콜라겐 분해효소-1 억제활성을 나타낸 그래프이다. 3 is a graph showing collagen degrading enzyme-1 inhibitory activity by xanthorrhizol of the present invention.

도 4는 본 발명의 잔토리졸(xanthorrhizol)에 의한 콜라겐 합성능을 나타낸 그래프이다. 4 is a graph showing collagen synthesis ability by xanthorrhizol of the present invention.

본 발명은 커큐마 잔토리자(Curcuma xanthorrhiza) 추출물 및 잔토리졸(xanthorrhizol)을 함유하는 주름개선 화장료 조성물에 관한 것으로서, 보다 상세하게는 하기 화학식 1로 표시되는 잔토리졸을 유효성분으로 함유하는 주름개선 화장료 조성물에 관한 것이다. The present invention relates to an anti-wrinkle cosmetic composition containing Curcuma xanthorrhiza extract and xanthorrhizol, and more particularly, containing xanthorzol represented by Chemical Formula 1 as an active ingredient. It relates to a wrinkle improvement cosmetic composition.

Figure 112007044421219-PAT00002
Figure 112007044421219-PAT00002

통상적으로 주름은 오랜 기간 동안 반복되는 근육운동으로 인해 형성되는 피부의 자연스러운 노화현상의 하나이다. 피부 노화는 크게 자연노화 혹은 내인성 노화와 외적 노화로 구분되며 자연노화는 유전적 원인에 의한 것이므로 조절이 어려우나 외적 노화는 환경적 원인에 의한 것이므로 인위적인 조절이 용이하다. 따라서 외적 노화를 방지하기 위한 연구가 지속되어 왔으며, 특히 장기간 자외선 노출에 의해 진행되는 외인성 광노화에 따른 주름 형성 방지에 대한 연구가 주목되고 있다(Gilchre st B.A., J. Am. Acad. Dermatol., 1989:21:610-613). Wrinkles are one of the natural aging phenomena of the skin, which are usually formed by repeated muscle movements over long periods of time. Skin aging is largely divided into natural aging or endogenous aging and external aging, and natural aging is due to genetic causes, which is difficult to control, but external aging is due to environmental causes, so artificial control is easy. Therefore, studies to prevent external aging have been continued, and in particular, research on preventing wrinkle formation caused by exogenous photoaging due to long-term ultraviolet exposure has been focused (Gilcher st BA, J. Am. Acad. Dermatol., 1989). : 21: 610-613).

외인성 피부노화인 광노화의 임상적 특징은 피부가 거칠고 탄력성이 없어지며, 불규칙한 색소 침착이 발생되고, 깊은 주름살이 증가되는 것이다. 특히 미용의 대상으로서 중요한 안면, 두부 등의 주름 형성에는 광노화의 영향이 큰 것으로 밝혀지고 있어 항주름 화장품 개발의 기초연구로서 인체 피부나 동물 모델을 이용한 광노화와 주름형성에 관한 연구가 활발히 진행되고 있다. 광노화와 주름 형성에 관해서는 지금까지 피부의 주요 구성성분인 콜라겐(collagen)의 합성, 분해 등의 기초적인 생리 대사 변화를 검토한 결과가 다수 보고되고 있다(Lavker R.M., Blackwell science Inc.,1995:123-135).The clinical characteristics of photoaging, which is exogenous skin aging, are that the skin becomes rough and elastic, irregular pigmentation occurs, and deep wrinkles increase. In particular, the effects of photoaging have been found to be important in the formation of facial wrinkles, such as facial and tofu, which are important for cosmetics. As a basic research for the development of anti-wrinkle cosmetics, research on photoaging and wrinkle formation using human skin or animal models has been actively conducted. . In regard to photoaging and wrinkle formation, many studies have reported basic physiological metabolic changes such as synthesis and degradation of collagen, a major component of skin (Lavker RM, Blackwell science Inc., 1995: 123-135).

피부노화에 영향을 미치는 외부인자들은 바람, 온도, 습도, 담배연기, 공해, 자외선 등에 의해서 노화가 일어나며 특히 자외선에 의한 노화를 광노화라고 한다. 많은 양의 자외선에 노출되면 피부에는 높은 농도의 활성산소(reactive oxygen species)가 생성되고 피부의 효소적, 비효소적 항산화 방어계를 붕괴시킨다. 이로 인해 피부조직의 주 단백질인 콜라겐(collagen)이 현저히 감소되고 이때 콜라겐 감소에 중요한 영향을 미치는 것이 콜라겐 분해 효소-1(MMP-1, matrix metalloproteinase-1)이다. 콜라겐 분해 효소-1은 세포외기질(extracellular matrix)과 기저막(basement membrane)의 분해에 관여하는 효소로 자외선 조사에 의해 피부내의 콜라겐 분해효소-1 활성이 증가되어 콜라겐을 현저하게 붕괴시킴으로써 콜라겐 분해효소-1들이 진피층의 콜라겐 붕괴에 영향을 미쳐 주름 형성에 매우 중요한 역할을 하고 있다는 연구 결과들이 보고되어 있다(Sim G.S., Kim J.H et al., Kor. J. Biotechnol. Bioeng., 2005:20(1):40-45). External factors affecting skin aging are caused by wind, temperature, humidity, tobacco smoke, pollution, ultraviolet rays, etc. In particular, aging caused by ultraviolet rays is called photoaging. Exposure to high amounts of ultraviolet light produces high levels of reactive oxygen species in the skin and disrupts the enzymatic and non-enzymatic antioxidant defenses of the skin. As a result, collagen, a major protein of skin tissue, is significantly reduced, and collagen degrading enzyme-1 (MMP-1, matrix metalloproteinase-1) has an important effect on collagen reduction. Collagen Degrading Enzyme-1 is an enzyme that is involved in the decomposition of extracellular matrix and basement membrane. Collagen degrading enzyme is significantly degraded by increasing collagen degrading enzyme-1 activity in the skin by UV irradiation. -1 have been reported to play an important role in the formation of wrinkles by influencing collagen breakdown of the dermis (Sim GS, Kim JH et al., Kor. J. Biotechnol. Bioeng., 2005: 20 (1) ): 40-45).

현재 개발되고 있는 피부 주름개선 유효성분들은 일부 화장품 원료로 사용할 수 없거나 매우 불안정하며, 피부로의 전달이 용이하지 않아 특별한 안정화 시스템과 전달체계가 필요하며, 피부주름의 개선효과가 가시적이지 않는 등의 문제점이 있어서 최근 레티노이드(retinoid)를 함유한 피부보호제로 관심이 점차 집중되고 있으며, 현재 레티노이드는 일광으로 축적된 결과인 주름살, 피부의 두꺼워짐, 처짐, 탄력 감소 등의 광노화 현상을 해결하는 수단으로 이용되고 있다. 그러나 레티노이드는 매우 불안정한 화합물로 자외선, 수분, 열, 산소에 민감하여 쉽게 화학적인 변화를 일으키는 문제점이 있어 이를 해결하기 위한 천연물 유래의 유효성분 개발에 연구가 집중되고 있는 실정이다.The active skin wrinkle improvement ingredients currently being developed cannot be used as some cosmetic ingredients or are very unstable, and it is not easy to transfer to the skin, so a special stabilization system and delivery system are needed, and the effect of improving wrinkles is not visible. Recently, attention has been focused on skin protection agents containing retinoids. Currently, retinoids are used as a means to solve photoaging phenomena such as wrinkles, skin thickening, sagging, and decreased elasticity, which are the result of daylight accumulation. It is used. However, retinoids are very unstable compounds and are sensitive to ultraviolet rays, moisture, heat, and oxygen, and easily cause chemical changes. Therefore, research is focused on developing active ingredients derived from natural products to solve them.

이에 본 발명자들은 주름개선에 효과적으로 사용될 수 있는 천연물 유래 화합물을 찾고자 장기간 탐색한 결과, 커큐마 잔토리자(Curcuma xanthorrhiza) 추출물로부터 분리·정제된 잔토리졸(xanthorrhizol)이 주름개선에 탁월한 효과를 가짐을 규명함으로써 본 발명을 완성하였다. Accordingly, the present inventors searched for a long time to find a natural-derived compound that can be effectively used for wrinkle improvement. As a result, xanthorrhizol separated and purified from Curcuma xanthorrhiza extract has an excellent effect on wrinkle improvement. The present invention was completed by identifying the following.

따라서, 본 발명의 목적은 커큐마 잔토리자 추출물로부터 분리·정제된 잔토리졸의 주름개선 효과와 이를 함유하는 화장료 조성물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide an anti-wrinkle effect of xantolizol separated and purified from curcuma xantoriza extract and a cosmetic composition containing the same.

상기와 같은 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 잔토리졸을 유효성분으로 함유하는 주름개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for improving wrinkles containing xantholizole represented by the following formula (1) as an active ingredient.

[화학식 1][Formula 1]

Figure 112007044421219-PAT00003
Figure 112007044421219-PAT00003

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명은 커큐마 잔토리자(Curcuma xanthorrhiza)로부터 분리·정제된 잔토리졸(xanthorrhizol)의 신규한 용도를 제공하는 데 그 특징이 있다.The present invention is characterized by providing a novel use of xanthorrhizol isolated and purified from Curcuma xanthorrhiza .

커큐마 잔토리자는 생강과(Zingiberaceae) 식물로서 일반적으로 temu lawak 또는 Javanese turmeric으로 알려진 인도네시아의 전통 약용식물로 주성분으로 artumenone, α-curcumene, β-curcumene, curzerenone, germacrone, β-sesquiphellandrene, α-turmerone, β-turmerone, xanthorrhizol 등의 terpenoid 계열 화합물과 7-30%의 essential oil, 30-40%의 carbohydrate, 그리고 0.02-2.0%의 방향성 색소인 curcuminoid 등을 포함하고 있다(Lin S. C. et al., Am. J. Chin. Med., 1995:23:243-254).   Curcuma zantorija is a traditional medicinal plant known as temu lawak or Javanese turmeric, which is known as the Zingiberaceae plant. , terpenoid compounds such as β-turmerone and xanthorrhizol, 7-30% essential oil, 30-40% carbohydrate, and curcuminoid, 0.02-2.0% aromatic pigment (Lin SC et al., Am J. Chin.Med., 1995: 23: 243-254).

잔토리졸은 커큐마 잔토리자에서 발견되는 대표적인 구성성분으로서 세스퀴테르펜(sesquiterpene)의 일종이다. 잔토리졸은 구강미생물에 대한 항균작용(Hwang, J. K. et al., Fitoterapia, 2000:71:321-323; Hwang, J. K. et al., Planta Medica, 2000:66:196-197), 항암제로 유발되는 독성의 억제활성(Kim, S. H. et al., Toxicology and Applied Pharmacology, 2004:196:346-355; Kim, S. H. et al., Food and Chemical Toxicology, 2005:43:117-122), 암전이억제작용(Choi, M. A. et al., Biochem. Biophys. Res. Commun., 2005:326:210-217) 등이 알려져 있다. 그러나 본 발명의 잔토리졸에 의한 주름개선 효과에 대해서는 지금까지 전혀 보고된 바 없다.Xantorisol is a type of sesquiterpene that is a representative constituent found in Curcuma xantoriza. Xantorizole is an antimicrobial agent for oral microorganisms (Hwang, JK et al., Fitoterapia, 2000: 71: 321-323; Hwang, JK et al., Planta Medica, 2000: 66: 196-197) Inhibitory activity of toxic effects (Kim, SH et al., Toxicology and Applied Pharmacology, 2004: 196: 346-355; Kim, SH et al., Food and Chemical Toxicology, 2005: 43: 117-122), inhibiting cancer metastasis Action (Choi, MA et al., Biochem. Biophys. Res. Commun., 2005: 326: 210-217) and the like are known. However, the wrinkle improvement effect of the xantholizole of the present invention has not been reported so far.

커큐마 잔토리자의 추출방법으로는 대한미국 공개특허공보 제2000-0000342호 및 PCT특허 제 WO88/05304에 개시된 바와 같이 유기용매추출법, 초임계유체 추출법, 마이크로웨이브 추출법 및 초음파 추출법 등이 사용될 수 있다. 커큐마 잔토리자 추출물로부터 잔토리졸을 분리·정제 하는 과정은 대한민국 공개특허공보 제2000-0073295호에 개시된 바 있다.As a method of extracting Curcuma zantorija, an organic solvent extraction method, a supercritical fluid extraction method, a microwave extraction method, and an ultrasonic extraction method may be used as disclosed in Korean Patent Application Publication No. 2000-0000342 and PCT Patent No. WO88 / 05304. . Separation and purification of xanthozol from the Curcuma xantoriza extract has been disclosed in Korean Patent Laid-Open Publication No. 2000-0073295.

상기에 개시된 본 발명의 커큐마 잔토리자 추출물과 잔토리졸은 자외선 조사에 의한 인체 피부섬유아세포(human skin fibroblast)에서 콜라겐 분해효소-1(MMP-1, matrix metalloproteinase-1)의 생성을 농도 의존적으로 억제하고, 콜라겐(type-1 procollagen) 합성을 증가시킨다.The curcuma zantoriza extract and xantholizole of the present invention disclosed above are used to increase the production of collagen degrading enzyme-1 (MMP-1, matrix metalloproteinase-1) in human skin fibroblasts by ultraviolet irradiation. Dependently and increases collagen (type-1 procollagen) synthesis.

또한 본 발명은 커큐마 잔토리자 추출물과 잔토리졸을 함유하는 화장료 조성물에 그 특징이 있다. In addition, the present invention is characterized by a cosmetic composition containing curcuma zantoriza extract and zantorazole.

커큐마 잔토리자 추출물과 잔토리졸은 유연화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 팩 등의 주름개선에 관련되는 모든 화장료에 첨가할 수 있으며, 첨가량은 화장료 조성물 총 중량에 대하여 0.005-10중량%, 바람직하게는 0.01-5중량%인 것이 바람직하다. 0.005중량% 이하의 농도에서는 주름개선 효과를 얻기 어려우며, 10중량% 이상으로 배합하면 사용량에 비하여 주름개선 효과의 증가가 미미하고, 조성물의 안정성 면에서 비경제적이다.Curcuma Xantoriza extract and Xantorizol can be added to all cosmetics related to wrinkle improvement such as softening cream, nutrient cream, nourishing cream, massage cream, essence, and pack, and the amount is 0.005 based on the total weight of the cosmetic composition. It is preferable that it is -10 weight%, preferably 0.01-5 weight%. When the concentration is less than 0.005% by weight, it is difficult to obtain an antiwrinkle effect, and when blended in an amount of 10% by weight or more, the increase of the antiwrinkle effect is insignificant compared to the amount used, and it is uneconomical in terms of stability of the composition.

이와 같이 본 발명의 커큐마 잔토리자 추출물과 잔토리졸은 자외선 조사에 의한 콜라겐 분해효소-1의 생성을 억제하는 효과와 콜라겐을 합성하는 효과가 매우 우수하다. 따라서 본 발명은 커큐마 잔토리자 추출물과 상기 화학식 1로 표시되는 잔토리졸을 유효성분으로 함유하는 주름개선 화장료 조성물을 제공한다. 상기 커큐마 잔토리자 추출물의 제조는 위에서 기재한 바와 같다.As described above, the curcuma zantoriza extract and xantholizole of the present invention are excellent in inhibiting the production of collagen degrading enzyme-1 by ultraviolet irradiation and synthesizing collagen. Accordingly, the present invention provides an anti-wrinkle cosmetic composition containing the curcuma zantoriza extract and the zantorazole represented by Chemical Formula 1 as an active ingredient. Preparation of the Curcuma Xantoriza extract is as described above.

이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.

단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

<실시예 1> <Example 1> 세포증식효과Cell proliferation effect

피부의 주름개선효과를 검정하는 세포증식효과를 보기 위하여 섬유아세포를 이용한 MTT 시험법[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide reduction method]을 수행하였다.MTT assay using fibroblasts [3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide reduction method] was performed to examine the cell proliferation effect of assaying the wrinkle improvement effect of skin.

먼저, 인체 정상 섬유아세포(human normal fibroblasts)를 96-웰 플레이트(96-well plate)의 각 웰에 2× 105 세포가 되도록 분주하여 소태아 혈청(fetal bovine serum) 10%가 함유된 디엠이엠(DMEM) 배지에서 37℃, 5% CO2 조건하에서 24시간 동안 1차 배양한다. 상기 1차 배양단계 이후에 본 발명의 시료를 농도별로 처리하여 시럼(serum)이 없는 배지로 교체하여 48시간 동안 2차 배양한다. 상기 2차 배양단계이후 MTT 용액 100 ㎕씩을 배지에 첨가한 후 4시간 동안 방치한 다음 배지를 제거한다. 각 웰당 디메칠설폭사이드(dimethyl sulfoxide) 용액 100 ㎕씩을 가하여 20분간 교반한 후 마이크로 플레이트 판독기(microplate reader)로 540 nm에서 흡광도를 측정하였다.First, human normal fibroblasts are dispensed into 2 × 10 5 cells in each well of a 96-well plate, so that the DM containing 10% fetal bovine serum is contained. (DMEM) First incubate for 24 hours at 37 ° C., 5% CO 2 conditions. After the first culturing step, the sample of the present invention is treated by concentration and replaced with a medium without serum (serum), followed by secondary culture for 48 hours. After the second incubation step, 100 μl of MTT solution was added to the medium and left for 4 hours, and then the medium was removed. 100 μl of dimethyl sulfoxide solution was added to each well, followed by stirring for 20 minutes, and the absorbance was measured at 540 nm using a microplate reader.

<실험예 1> Experimental Example 1 커큐마 잔토리자 추출물과 잔토리졸의 세포증식효과Cell Proliferation Effect of Curcuma Xantoriza Extract and Xantorizol

상기 실시예 1의 방법에 따라 커큐마 잔토리자 에탄올 추출물과 잔토리졸의 세포증식 효과를 측정하였다. 상기 MTT 시험에서의 대조군은 시료를 처리하지 않은 배양액으로 설정한 후 흡광도를 측정하였고, 피부 주름개선 효과가 있는 것으로 알려진 녹차추출물(green tea extract)과 에피갈로카테킨 갈레이트(epigallocatechin-3-gallate, EGCG)를 비교군으로 설정하였으며, 그 결과를 하기 표 1에 나타내었다.According to the method of Example 1, the cell proliferation effect of Curcuma zantorija ethanol extract and zantorazole was measured. The control group in the MTT test was set to the culture medium without the sample, the absorbance was measured, green tea extract and epigallocatechin gallate (epigallocatechin-3-gallate) known to have skin wrinkle improvement effect , EGCG) was set as a comparison group, and the results are shown in Table 1 below.

증식효과(%)Proliferation effect (%) 농도(㎍/ml)Concentration (㎍ / ml) 커큐마 잔토리자 에탄올 추출물Curcuma Xanturiza Ethanol Extract 잔토리졸Xantorisol 녹차 추출물Green tea extract EGCGEGCG 00 100100 100100 100100 100100 0.0010.001 101101 101101 102102 101101 0.010.01 101101 105105 102102 106106 0.10.1 108108 110110 104104 108108 1One 119119 125125 117117 121121 1010 127127 127127 120120 123123 5050 132132 135135 127127 128128

표 1에서 보는 바와 같이, 본 발명의 커큐마 잔토리자 에탄올 추출물과 잔토리졸은 비교군보다 세포증식 효과가 우수한 것을 확인할 수 있었다.As shown in Table 1, it was confirmed that the curcuma zantorija ethanol extract and xantholizole of the present invention is superior to the cell proliferation effect than the comparison group.

<실시예 2> <Example 2> 섬유아세포 자외선 조사에 따른 콜라겐 분해효소-1 및 콜라겐 생합성 Collagen Biosynthesis-1 and Collagen Biosynthesis by Ultraviolet Irradiation of Fibroblasts

측정Measure

섬유아세포를 2× 105 cells/ml의 농도로 60 mm 디쉬(dish)에 배양하고 약 85% 수준에 도달할 때 까지 배양한다. 자외선(UV) 조사 전에 배지를 제거한 후 PBS로 세척하여 배지 내 시럼 성분을 제거한 후 20 mJ/cm2의 조사량으로 자외선을 조사하였다. 섬유아세포에 자외선을 조사한 후 시료를 처리하여 48시간 동안 배양한 배지를 이용하여 콜라겐 분해효소-1 및 콜라겐의 발현 정도를 측정하였다. The fibroblasts are incubated in a 60 mm dish at a concentration of 2 × 10 5 cells / ml and incubated until reaching 85% level. After the medium was removed before UV (UV) irradiation, the medium was washed with PBS to remove the rum component in the medium, and the UV was irradiated at a dose of 20 mJ / cm 2 . Fibroblasts were irradiated with UV light and the samples were treated and cultured for 48 hours, and the expression levels of collagenase-1 and collagen were measured.

콜라겐 분해효소-1과 콜라겐 생합성 발현양을 측정하기 위해 웨스턴 블랏(western blot)법을 이용하였고, 섬유아세포가 배양된 배지 내의 총 단백질 양은 브래드포드(Bradford)법을 이용하여 정량하였다. Western blot was used to measure the expression levels of collagen degrading enzyme-1 and collagen biosynthesis, and the total protein amount in the culture medium in which fibroblasts were cultured was quantified using the Bradford method.

추출된 단백질은 10% SDS-폴리아크릴아미드 겔에 전기영동 시킨 후 니트로셀룰로오스 세포막(nitrocellulose membrane)으로 겔의 단백질을 전이시켰다. 멤브레인이 더 이상 다른 미지의 단백질에 의해 오염이 되지 않도록 5% 탈지분유(5% skim milk)을 이용하여 1시간 동안 상온에서 차단하고, 콜라겐 분해효소-1(MMP-1)와 콜라겐(type-1 procollagen)의 1차 항체를 blocking solution에 1:1000의 비율로 희석하여 2시간동안 상온에서 반응시켰다. 1차 항체 반응 후 10분씩 3회에 걸쳐 TBST(Tris-buffer Saline Tween 20)로 흔들어주며 세척하였다. 콜라겐 분해효소-1(MMP-1)과 콜라겐(type-1 procollagen)의 1차 항체를 인지하는 2차 항체를 5% 탈지분유에 1:1000이 되도록 희석하여 1시 간 동안 상온에서 반응시키고 1차 항체 때와 마찬가지로 10분씩 3회에 걸쳐 TBST(tris-buffer saline Tween 20)로 흔들어주며 세척한 다음 화학발광법(chemiluminescence)으로 현상하였다.The extracted protein was electrophoresed on 10% SDS-polyacrylamide gel and then transferred to the nitrocellulose membrane. The membrane is blocked at room temperature for 1 hour using 5% skim milk so that the membrane is no longer contaminated by other unknown proteins. Collagen degrading enzyme-1 (MMP-1) and collagen (type-) 1 procollagen) primary antibody was diluted 1: 1000 in a blocking solution and reacted at room temperature for 2 hours. After the first antibody reaction, the solution was shaken with TBST (Tris-buffer Saline Tween 20) three times for 10 minutes. A secondary antibody that recognizes primary antibodies of collagen degrading enzyme-1 (MMP-1) and collagen (type-1 procollagen) is diluted 1: 1000 in 5% skim milk powder and reacted at room temperature for 1 hour. As in the case of the primary antibody, the solution was shaken with tris-buffer saline Tween 20 (TBST) three times for 10 minutes and then developed by chemiluminescence.

<실험예 2> Experimental Example 2 커큐마 잔토리자 에탄올 추출물 처리 시 콜라겐 분해효소-1 및 Collagen Degrading Enzyme-1 and Curcuma Xantoriza Ethanol Extract Treatment

콜라겐 발현양 측정Measurement of collagen expression

커큐마 잔토리자 에탄올 추출물의 콜라겐 분해효소-1 억제 활성과 콜라겐 합성 효과를 측정하기 위해 상기 실시예 2의 웨스턴 블랏법을 이용하여 발현양을 조사한 결과 커큐마 잔토리자 에탄올 추출물을 처리했을 때 콜라겐 분해효소-1이 농도 의존적으로 억제되고 콜라겐 합성 또한 농도 의존적으로 증가되는 것을 확인하였다. 그 결과를 도 1과 도 2에 각각 나타내었다. 도 1에서 보는 바와 같이 커큐마 잔토리자 에탄올 추출물을 처리했을 때 0.01 ㎍/ml에서 16%, 0.1 ㎍/ml에서 28%, 0.5 ㎍/ml에서 78%의 콜라겐 분해효소-1 억제 활성을 나타냈고, 또한 도 2에서 보는 바와 같이 커큐마 잔토리자 에탄올 추출물을 처리했을 때 0.01 ㎍/ml에서 24%, 0.1 ㎍/ml에서 127%, 0.5 ㎍/ml에서 196%의 콜라겐 합성 촉진 효과를 나타냈다. In order to determine the collagenase-1 inhibitory activity and collagen synthesis effect of Curcuma zantorija ethanol extract, the expression level was investigated using the Western blot method of Example 2, and when Curcuma zantorija ethanol extract was treated. It was confirmed that collagenase-1 was inhibited in a concentration-dependent manner and collagen synthesis was also increased in a concentration-dependent manner. The results are shown in FIGS. 1 and 2, respectively. As shown in FIG. 1, when curcuma zantorija ethanol extract was treated, it showed 16% at 0.01 μg / ml, 28% at 0.1 μg / ml, and 78% at 0.5 μg / ml. Also, as shown in FIG. 2, the Curcuma zantorija ethanol extract showed a collagen synthesis promoting effect of 24% at 0.01 μg / ml, 127% at 0.1 μg / ml and 196% at 0.5 μg / ml. .

<실험예 3> Experimental Example 3 커큐마 잔토리자 헥산 추출물 처리 시 콜라겐 분해효소-1 및 Collagen Degrading Enzyme-1 and Curcuma Xantoriza Hexane Extract Treatment

콜라겐 발현양 측정Measurement of collagen expression

커큐마 잔토리자 헥산 추출물에 대하여 콜라겐 분해효소-1 억제 활성과 콜라겐 합성 효과를 측정하기 위해 상기 실시예 2의 웨스턴 블랏법을 이용하여 발현양을 조사한 결과 실험예 2에서 커큐마 잔토리자 에탄올 추출물을 처리했을 때와 유사한 활성을 보여 콜라겐 분해효소-1은 0.5 ㎍/ml에서 75% 억제되었고, 콜라겐 합성은 동일 농도에서 191% 증가되는 활성을 보였다. In order to determine the collagenase-1 inhibitory activity and collagen synthesis effect against Curcuma zantoriza hexane extract, the expression level was investigated using the Western blot method of Example 2, and Curcuma zantoriza ethanol in Experimental Example 2 Collagen degrading enzyme-1 showed 75% inhibition at 0.5 ㎍ / ml and collagen synthesis increased 191% at the same concentration.

<실험예 4> Experimental Example 4 잔토리졸 처리 시 콜라겐 분해효소-1 및 콜라겐 발현양 측정Determination of Collagen Degrading Enzyme-1 and Collagen Expression Levels

잔토리졸의 콜라겐 분해효소-1 억제 활성과 콜라겐 합성 효과를 측정하기 위해 상기 실시예 2의 웨스턴 블랏법을 이용하여 발현양을 조사한 결과 잔토리졸을 처리했을 때 콜라겐 분해효소-1이 농도 의존적으로 억제되고 콜라겐 합성 또한 농도 의존적으로 증가되는 것을 확인하였다. 그 결과를 도 3과 도 4에 각각 나타내었다. 도 3에서 보는 바와 같이 잔토리졸을 처리했을 때 0.001 μM에서 18%, 0.01 μM에서 68%, 0.1 μM에서 92%의 콜라겐 분해효소-1 억제 활성을 나타냈고, 이때 동일 농도인 0.1 μM에서 비교하였을 때 비교군인 EGCG는 72%의 콜라겐 분해효소-1 억제활성을 나타내어 잔토리졸 처리에 의한 활성이 높은 것을 확인하였다. 또한 도 4에서 보는 바와 같이 잔토리졸을 처리했을 때 0.01 μM에서 57%, 0.1 μM에서 86%의 콜라겐 합성 촉진 효과를 나타냈고, 이때 동일 농도인 0.1 μM에서 비교하였을 때 비교군인 EGCG는 65%의 콜라겐 합성 촉진 활성을 나타내어 잔토리졸 처리에 의한 활성이 높은 것을 확인하였다. 따라서 본 발명의 잔토리졸은 주름개선에 효과가 있는 것으로 잘 알려진 EGCG보다 활성이 높은 것으로 최종 확인되었다.In order to measure the collagen degrading enzyme-1 inhibitory activity and collagen synthesis effect of xantholizol, the expression level was examined using the western blot method of Example 2, and the concentration of collagen degrading enzyme-1 when Xantolizol was treated And collagen synthesis also increased in a concentration dependent manner. The results are shown in FIGS. 3 and 4, respectively. As shown in FIG. 3, xantholizole showed 18% collagenase-1 inhibitory activity at 0.001 μM, 68% at 0.01 μM, and 92% at 0.1 μM, compared to 0.1 μM at the same concentration. When compared with EGCG showed a 72% collagenase-1 inhibitory activity, it was confirmed that the activity by the xantholizol treatment is high. In addition, as shown in Figure 4 when treated with xantholizol showed a collagen synthesis promoting effect of 57% at 0.01 μM, 86% at 0.1 μM, when compared with the same concentration of 0.1 μM 65% compared to EGCG group Showed collagen synthesis promoting activity and confirmed that the activity by xantholizole treatment was high. Therefore, xantolizole of the present invention was finally confirmed to have higher activity than EGCG, which is known to have an effect on wrinkle improvement.

<실시예 3-6> <Example 3-6> 커큐마 잔토리자 추출물을 함유하는 화장수의 제조Preparation of lotion containing curcuma zantoriza extract

커큐마 잔토리자 에탄올 추출물을 이용하여 실시예 3-6의 조성을 지니는 화장수를 제조하였다. 추출물을 10.0, 1.0, 0.1, 0.01중량%의 4가지 농도로 하여 각각 에탄올 일정량에 녹인A lotion having the composition of Example 3-6 was prepared using Curcuma zantorija ethanol extract. The extracts were dissolved in a certain amount of ethanol in four concentrations of 10.0, 1.0, 0.1, and 0.01% by weight.

실시예 3Example 3 실시예 4Example 4 실시예 5Example 5 실시예 6Example 6 조추출물 10.0%Crude extract 10.0% 조추출물 1.0%Crude extract 1.0% 조추출물 0.1%Crude extract 0.1% 조추출물 0.01%Crude extract 0.01% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 인산 칼륨 0.1% Potassium Phosphate 0.1% 인산 칼륨 0.1%Potassium Phosphate 0.1% 인산 칼륨 0.1%Potassium Phosphate 0.1% 인산 칼륨 0.1%Potassium Phosphate 0.1% 인산2나트륨 0.05%Sodium Diphosphate 0.05% 인산2나트륨 0.05%Sodium Diphosphate 0.05% 인산2나트륨 0.05%Sodium Diphosphate 0.05% 인산2나트륨 0.05%Sodium Diphosphate 0.05% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 에탄올(96%) 20%Ethanol (96%) 20% 에탄올(96%) 20%Ethanol (96%) 20% 에탄올(96%) 20%Ethanol (96%) 20% 에탄올(96%) 20%Ethanol (96%) 20% 정제수 잔부Purified water balance 정제수 잔부Purified water balance 정제수 잔부Purified water balance 정제수 잔부Purified water balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance

다음 에탄올로서 중량을 조정하고, 고르게 혼화시켰다. The weight was then adjusted as ethanol and mixed evenly.

<실시예 7-10> <Example 7-10> 커큐마 잔토리자 추출물을 함유하는 크림의 제조Preparation of Cream Containing Curcuma Xantoriza Extract

커큐마 잔토리자 에탄올 추출물을 이용하여 실시예 7-10의 조성을 지니는 크림을 제조하였다. 먼저 표시된 ①-⑤물질은 75-80℃에서 녹이고, ⑥-⑨물질을 같은 온도에서 녹인다. ⑥-⑨물질을 ①-⑤물질에 유화시킨 다음 조추출물을 10.0, 1.0, 0.1, 0.01%의 농도로 각각 넣어 재혼합한 후 마지막으로 향료를 넣고 정제수로 정량을 맞춘다.A cream having the composition of Example 7-10 was prepared using Curcuma Xantoriza ethanol extract. Firstly, ①-⑤ material is dissolved at 75-80 ℃, and ⑥-⑨ material is melted at the same temperature. Emulsify ⑥-⑨ material into ①-⑤ material, add crude extracts at the concentrations of 10.0, 1.0, 0.1, and 0.01%, and remix them.

실시예 7Example 7 실시예 8Example 8 실시예 9Example 9 실시예 10Example 10 조추출물 10.0%Crude extract 10.0% 조추출물 1.0%Crude extract 1.0% 조추출물 0.1%Crude extract 0.1% 조추출물 0.01%Crude extract 0.01% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 염화 라우릴 설파이드 8.0%Lauryl chloride sulfide 8.0% 염화 라우릴 설파이드 8.0%Lauryl chloride sulfide 8.0% 염화 라우릴 설파이드 8.0%Lauryl chloride sulfide 8.0% 염화 라우릴 설파이드 8.0%Lauryl chloride sulfide 8.0% 스테아린 5.4%Stearin 5.4% 스테아린 5.4%Stearin 5.4% 스테아린 5.4%Stearin 5.4% 스테아린 5.4%Stearin 5.4% 미네랄 오일 4.5%Mineral oil 4.5% 미네랄 오일 4.5%Mineral oil 4.5% 미네랄 오일 4.5%Mineral oil 4.5% 미네랄 오일 4.5%Mineral oil 4.5% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 세틸 알코올 6.5%Cetyl alcohol 6.5% 세틸 알코올 6.5%Cetyl alcohol 6.5% 세틸 알코올 6.5%Cetyl alcohol 6.5% 세틸 알코올 6.5%Cetyl alcohol 6.5% 정제수 잔부Purified water balance 정제수 잔부Purified water balance 정제수 잔부Purified water balance 정제수 잔부Purified water balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance

<실시예 11-14> <Example 11-14> 잔토리졸을 함유하는 화장수의 제조Preparation of Lotion Containing Xanthozol

본 발명의 잔토리졸을 이용하여 실시예 11-14의 조성을 지니는 화장수를 제조하였다. 잔토리졸을 5.0, 0.1, 0.01, 0.001%의 4가지 농도로 하여 각각 물 일정량에 녹인 다음 인산 수용액과 혼합한다. 에탄올과 글리세린, 프로필렌글리콜을 섞어 앞에서 제조한 혼합물에 넣어 혼합하면서 향료, 보존료를 추가하여 물로서 중량을 조정하고, 고르게 혼화시킨다.Using the xantholizole of the present invention, a lotion having the composition of Example 11-14 was prepared. Xantolizole is dissolved in a predetermined amount of water at four concentrations of 5.0, 0.1, 0.01, and 0.001%, and then mixed with an aqueous solution of phosphoric acid. Mix ethanol, glycerin, and propylene glycol, mix in the mixture prepared above, add fragrance and preservative, adjust the weight as water, and mix evenly.

실시예 11Example 11 실시예 12Example 12 실시예 13Example 13 실시예 14Example 14 잔토리졸 5.0%Xantolizol 5.0% 잔토리졸 0.1%Xantolizole 0.1% 잔토리졸 0.01%Xantolizole 0.01% 잔토리졸 0.001%Xanthozol 0.001% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 인산 칼륨 0.1% Potassium Phosphate 0.1% 인산 칼륨 0.1%Potassium Phosphate 0.1% 인산 칼륨 0.1%Potassium Phosphate 0.1% 인산 칼륨 0.1%Potassium Phosphate 0.1% 인산2나트륨 0.05%Sodium Diphosphate 0.05% 인산2나트륨 0.05%Sodium Diphosphate 0.05% 인산2나트륨 0.05%Sodium Diphosphate 0.05% 인산2나트륨 0.05%Sodium Diphosphate 0.05% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 에탄올(96%) 20%Ethanol (96%) 20% 에탄올(96%) 20%Ethanol (96%) 20% 에탄올(96%) 20%Ethanol (96%) 20% 에탄올(96%) 20%Ethanol (96%) 20% 정제수 잔부Purified water balance 정제수 잔부Purified water balance 정제수 잔부Purified water balance 정제수 잔부Purified water balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance

<실시예 15-18> <Example 15-18> 잔토리졸을 함유하는 크림의 제조Preparation of a Cream Containing Xanthozol

본 발명의 잔토리졸을 이용하여 실시예 15-18의 조성을 지니는 크림을 제조하였다. 먼저 표시된 ①-⑤물질은 75-80℃에서 녹이고, ⑥-⑨물질을 같은 온도에서 녹인다. ⑥-⑨물질을 ①-⑤물질에 유화시킨 다음 잔토리졸을 5.0, 0.1, 0.01, 0.001%의 농도로 각각 넣어 재혼합한 후 마지막으로 향료를 넣고 정제수로 정량을 맞춘다.A cream having the composition of Examples 15-18 was prepared using the xantholizole of the present invention. Firstly, ①-⑤ material is dissolved at 75-80 ℃, and ⑥-⑨ material is melted at the same temperature. Emulsify ⑥-⑨ materials into ①-⑤ materials, add xantholizol at concentrations of 5.0, 0.1, 0.01, and 0.001%, respectively, and remix them. Finally, add spices and quantify with purified water.

실시예 15Example 15 실시예 16Example 16 실시예 17Example 17 실시예 18Example 18 잔토리졸 5.0%Xantolizol 5.0% 잔토리졸 0.1%Xantolizole 0.1% 잔토리졸 0.01%Xantolizole 0.01% 잔토리졸 0.001%Xanthozol 0.001% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 글리세린 2.0%Glycerin 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 프로필렌글리콜 2.0%Propylene Glycol 2.0% 염화 라우릴 설파이드 8.0%Lauryl chloride sulfide 8.0% 염화 라우릴 설파이드 8.0%Lauryl chloride sulfide 8.0% 염화 라우릴 설파이드 8.0%Lauryl chloride sulfide 8.0% 염화 라우릴 설파이드 8.0%Lauryl chloride sulfide 8.0% 스테아린 5.4%Stearin 5.4% 스테아린 5.4%Stearin 5.4% 스테아린 5.4%Stearin 5.4% 스테아린 5.4%Stearin 5.4% 미네랄 오일 4.5%Mineral oil 4.5% 미네랄 오일 4.5%Mineral oil 4.5% 미네랄 오일 4.5%Mineral oil 4.5% 미네랄 오일 4.5%Mineral oil 4.5% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 향료 0.02%Fragrance 0.02% 세틸 알코올 6.5%Cetyl alcohol 6.5% 세틸 알코올 6.5%Cetyl alcohol 6.5% 세틸 알코올 6.5%Cetyl alcohol 6.5% 세틸 알코올 6.5%Cetyl alcohol 6.5% 정제수 잔부Purified water balance 정제수 잔부Purified water balance 정제수 잔부Purified water balance 정제수 잔부Purified water balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance 보존료 잔부Preservative balance

<실험예 5> Experimental Example 5 커큐마 잔토리자 추출물 함유 조성물의 콜라겐 합성량 측정Determination of Collagen Synthesis of Curcuma Xantoriza Extract-Containing Composition

(( In vivoIn vivo ))

털없는 쥐(hairless mouse)에 자외선을 4주간 매일 1회 (UV 20 mJ/cm2) 조사한 후 상기 실시예 3-10의 커큐마 잔토리자 에탄올 추출물 함유 조성물을 각각 4주간 매일 100 ml씩 등부위에 도포한 후 생검하여 조직학적으로 콜라겐의 형성을 측정하였다. 이때 새로이 생성되는 콜라겐 양의 측정은 면역 염색한 후 이를 화상분석을 통하여 측정하였다. 그 결과를 하기 표 2에 나타내었다. The hairless mouse was irradiated with UV rays once daily for 4 weeks (UV 20 mJ / cm 2 ), and then 100 ml of the Curcuma Xantoriza ethanol extract-containing composition of Example 3-10 was applied for 4 weeks each day for 4 weeks. After application, the biopsy was performed and histologically measured the formation of collagen. At this time, the amount of newly produced collagen was measured by image analysis after immunostaining. The results are shown in Table 2 below.

콜라겐 증가율(%)Collagen Growth Rate (%) 무처리No treatment 00 화장수toilet water 실시예 3Example 3 34.834.8 화장수toilet water 실시예 4Example 4 21.221.2 화장수toilet water 실시예 5Example 5 8.48.4 화장수toilet water 실시예 6Example 6 3.53.5 크림cream 실시예 7Example 7 35.735.7 크림cream 실시예 8Example 8 23.123.1 크림cream 실시예 9Example 9 10.210.2 크림cream 실시예 10Example 10 4.14.1

상기 표 2에서 보는 바와 같이 커큐마 잔토리자 에탄올 추출물의 함량이 증가 될수록 콜라겐 합성량이 증가되었고, 화장수보다 크림의 경우 좀 더 높은 활성을 나타내는 것을 확인 할 수 있었다. 이는 화장수 보다 크림의 잔존력이 더 높기 때문일 것으로 판단된다.As shown in Table 2, as the content of Curcuma zantorija ethanol extract was increased, the collagen synthesis amount was increased, and it was confirmed that the cream had higher activity than the lotion. This is because the cream has a higher residual power than the lotion.

<실험예 6> Experimental Example 6 잔토리졸 함유 조성물의 콜라겐 합성량 측정(Determination of collagen synthesis amount of xantholizole containing composition ( In vivoIn vivo ))

털없는 쥐(hairless mouse)에 자외선을 4주간 매일 1회 (UV 20 mJ/cm2) 조사한 후 상기 실시예 11-18의 잔토리졸 함유 조성물을 각각 4주간 매일 100 ml씩 등부위에 도포한 후 생검하여 조직학적으로 콜라겐의 형성을 측정하였다. 이때 새로이 생성되는 콜라겐 양의 측정은 면역 염색한 후 이를 화상분석을 통하여 측정하였다. 그 결과를 하기 표 3에 나타내었다. After irradiating the hairless mouse with UV rays once daily for 4 weeks (UV 20 mJ / cm 2 ), the xantholizole-containing composition of Example 11-18 was applied to the back area for 4 weeks each day for 4 weeks. Biopsy was performed to histologically determine collagen formation. At this time, the amount of newly produced collagen was measured by image analysis after immunostaining. The results are shown in Table 3 below.

콜라겐 증가율(%)Collagen Growth Rate (%) 무처리No treatment 00 화장수toilet water 실시예 11Example 11 75.475.4 화장수toilet water 실시예 12Example 12 32.732.7 화장수toilet water 실시예 13Example 13 18.318.3 화장수toilet water 실시예 14Example 14 8.98.9 크림cream 실시예 15Example 15 77.677.6 크림cream 실시예 16Example 16 38.138.1 크림cream 실시예 17Example 17 20.820.8 크림cream 실시예 18Example 18 9.09.0

상기 표 3에서 보는 바와 같이 잔토리졸의 함량이 증가될수록 콜라겐 합성량이 증가되었고, 화장수보다 크림의 경우 좀 더 높은 활성을 나타내는 것을 확인 할 수 있었다. 이는 화장수 보다 크림의 잔존력이 더 높기 때문일 것으로 판단된다.As shown in Table 3, the content of xantholizole increased as collagen synthesis amount increased, and it was confirmed that the cream had higher activity than cream lotion. This is because the cream has a higher residual power than the lotion.

이상 살펴본 바와 같이, 본 발명의 커큐마 잔토리자(Curcuma xanthorrhiza) 추출물, 잔토리졸(xanthorrhizol) 및 이를 함유한 화장료 조성물은 주름 형성과 관련된 중요 요소인 콜라겐 분해효소-1(MMP-1, matrix metalloproteinase-1)의 발현을 억제함으로써 새로운 콜라겐(type-1 procollagen)의 생성을 촉진시켜 광노화에 의한 주름을 개선하는 효과가 있다. 따라서 본 발명의 커큐마 잔토리자 추출물과 잔토리졸을 유효성분으로 함유하는 화장료 조성물은 광노화에 의한 주름 개선의 치료 또는 예방에 매우 유용하게 사용될 수 있다.As described above, the curcuma xanthorrhiza extract of the present invention, xanthorrhizol and the cosmetic composition containing the same are important factors related to wrinkle formation collagen degrading enzyme-1 (MMP-1, matrix By inhibiting the expression of metalloproteinase-1), it is possible to promote the production of new collagen (type-1 procollagen) to improve wrinkles by photoaging. Therefore, the cosmetic composition containing the curcuma zantoriza extract of the present invention and zantorazole as an active ingredient can be very useful for the treatment or prevention of wrinkle improvement by photoaging.

Claims (9)

하기 화학식 1로 표시되는 잔토리졸(xanthorrhizol)을 유효성분으로 하는 콜라겐 분해효소-1 억제제(matrix metalloproteinase-1 inhibitor). Collagen degrading enzyme-1 inhibitor (matrix metalloproteinase-1 inhibitor) using the xanthorrhizol represented by the formula (1) as an active ingredient. [화학식 1][Formula 1]
Figure 112007044421219-PAT00004
Figure 112007044421219-PAT00004
하기 화학식 1로 표시되는 잔토리졸(xanthorrhizol)을 유효성분으로 하는 콜라겐 생합성제(collagen synthesizing agent).Collagen synthesizing agent (xanthorrhizol) represented by the formula (1) as an active ingredient (collagen synthesizing agent). [화학식 1][Formula 1]
Figure 112007044421219-PAT00005
Figure 112007044421219-PAT00005
하기 화학식 1로 표시되는 잔토리졸(xanthorrhizol)을 유효성분으로 함유하는 피부 주름개선용 화장료 조성물.       A cosmetic composition for improving skin wrinkles containing xanthorrhizol represented by the following Chemical Formula 1 as an active ingredient. [화학식 1]      [Formula 1]
Figure 112007044421219-PAT00006
Figure 112007044421219-PAT00006
제 3항에 있어서, 상기 잔토리졸은 커큐마 잔토리자(Curcuma xanthorrhiza)로부터 추출된 것을 특징으로 하는 피부 주름개선용 화장료 조성물.The cosmetic composition for improving skin wrinkles according to claim 3, wherein the xantholizole is extracted from Curcuma xanthorrhiza . 제 3항에 있어서, 상기 잔토리졸은 전체 화장료 조성물에 대하여 0.005 내지 5중량%로 함유되는 것을 특징으로 하는 피부 주름개선용 화장료 조성물.The cosmetic composition for improving skin wrinkles according to claim 3, wherein the xantholizole is contained in an amount of 0.005 to 5% by weight based on the total cosmetic composition. 제 3항 내지 제 5항에서 선택되는 어느 한 항에 있어서, 상기 피부 주름개선용 화장료 조성물은 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 젤, 파우더, 보디로션, 보디크림, 보디오일 및 보디에센스로 이루어진 군으로부터 선택된 어느 하나의 제형으로 이루어지는 것을 특징으로 하는 피부 주름개선용 화장료 조성물.The cosmetic composition for improving skin wrinkles according to any one of claims 3 to 5, wherein the cosmetic composition for improving skin wrinkles is a softening longevity, astringent longevity, nourishing longevity, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, Cleansing foam, cleansing water, packs, gels, powders, body lotions, body creams, body oils and body essences of any one selected from the group consisting of a cosmetic composition for improving skin wrinkles. 커큐마 잔토리자 추출물을 유효성분으로 함유하는 피부 주름개선용 화장료 조성물.A cosmetic composition for improving skin wrinkles containing Curcuma zantoriza extract as an active ingredient. 제 7항에 있어서, 상기 커큐마 잔토리자 추출물은 전체 화장료 조성물에 대하여 0.01 내지 10중량%로 함유되는 것을 특징으로 하는 피부 주름개선용 화장료 조성물.The cosmetic composition for improving skin wrinkles according to claim 7, wherein the curcuma zantorija extract is contained in an amount of 0.01 to 10% by weight based on the total cosmetic composition. 제 7항 내지 제 8항에서 선택되는 어느 한 항에 있어서, 상기 피부 주름개선용 화장료 조성물은 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 젤, 파우더, 보디로션, 보디크림, 보디오일 및 보디에센스로 이루어진 군으로부터 선택된 어느 하나의 제형으로 이루어지는 것을 특징으로 하는 피부 주름개선용 화장료 조성물.The method according to any one of claims 7 to 8, wherein the cosmetic composition for improving skin wrinkles is softening longevity, astringent longevity, nourishing longevity, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, Cleansing foam, cleansing water, packs, gels, powders, body lotions, body creams, body oils and body essences of any one selected from the group consisting of a cosmetic composition for improving skin wrinkles.
KR1020070060177A 2007-06-20 2007-06-20 Anti-wrinkle cosmetic composition Active KR101416993B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020070060177A KR101416993B1 (en) 2007-06-20 2007-06-20 Anti-wrinkle cosmetic composition
PCT/KR2008/003522 WO2008156330A1 (en) 2007-06-20 2008-06-20 Use of xanthorrhizol for anti-wrinkle treatment
JP2010513123A JP2010530412A (en) 2007-06-20 2008-06-20 Use of xanthorizole for skin wrinkle improvement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070060177A KR101416993B1 (en) 2007-06-20 2007-06-20 Anti-wrinkle cosmetic composition

Publications (2)

Publication Number Publication Date
KR20080111790A true KR20080111790A (en) 2008-12-24
KR101416993B1 KR101416993B1 (en) 2014-07-08

Family

ID=40156407

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070060177A Active KR101416993B1 (en) 2007-06-20 2007-06-20 Anti-wrinkle cosmetic composition

Country Status (3)

Country Link
JP (1) JP2010530412A (en)
KR (1) KR101416993B1 (en)
WO (1) WO2008156330A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101309335B1 (en) * 2010-06-30 2013-09-16 (주)아모레퍼시픽 Composition for regulating collagen

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5927047B2 (en) * 2011-06-09 2016-05-25 花王株式会社 TRPV3 activator
FR3005830B1 (en) * 2013-05-24 2015-08-28 Distrib Et De Prestation De Services Sdp Soc D COMPOSITION COMPRISING AT LEAST ONE ACTIVE SUBSTANCE FROM THE VEGETABLE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067711A1 (en) * 1999-05-08 2000-11-16 Hwang, Jae-Kwan A process for preparing xanthorrizol from curcuma xanthorriza roxb. and novel uses of the same
RU2004122120A (en) * 2001-12-18 2005-06-10 Хенкель Кгаа (De) Slowdown of the asexual reproduction of mushrooms
KR20030069391A (en) * 2002-02-20 2003-08-27 주식회사 엘지생활건강 Cosmetic compositions with anti-bacterial agents against body malodor
JP2004002267A (en) * 2002-03-28 2004-01-08 Kobayashi Pharmaceut Co Ltd Collagenase inhibitor and its utilization
JP2004075632A (en) * 2002-08-21 2004-03-11 Noevir Co Ltd Dermatofibroblast activator
JP2005239715A (en) * 2004-02-04 2005-09-08 Omboon Luanratana Medicinal cosmetic composition to alleviate photoaging
US7514092B2 (en) * 2004-12-22 2009-04-07 Avon Products, Inc. Compositions and methods of their use for improving the condition and appearance of skin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101309335B1 (en) * 2010-06-30 2013-09-16 (주)아모레퍼시픽 Composition for regulating collagen

Also Published As

Publication number Publication date
KR101416993B1 (en) 2014-07-08
JP2010530412A (en) 2010-09-09
WO2008156330A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
Hwang et al. UV radiation-induced skin aging in hairless mice is effectively prevented by oral intake of sea buckthorn (Hippophae rhamnoides L.) fruit blend for 6 weeks through MMP suppression and increase of SOD activity
JP2010006708A (en) External preparation for skin, bleaching agent, anti-aging agent and anti-oxidizing agent
EP2170255B1 (en) Use of lignan compound for anti-wrinkle treatment
KR20180038639A (en) Cosmetic Composition with Fermentative Extract of Osmanthus fragrans
KR101634668B1 (en) Cosmetic composition comprising fermented extract of mistletoe for anti-oxidation or whitening
KR101176528B1 (en) Cosmetic composition comprising the extract of salvia plebeia as active ingredient
KR101131574B1 (en) Composition for skin whitening
KR101873025B1 (en) Cosmetic composition containing complex extract of oriental plants
KR20130057091A (en) Skin external composition containing extracts of chrysanthemum indicum var. albescens
KR20080111790A (en) Wrinkle improvement cosmetic composition
KR100903654B1 (en) Cosmetic composition containing Hachocho extract and adenosine
KR101303807B1 (en) Cosmetic composition having anti-aging effect
KR101172058B1 (en) A composition for skin external application for improving skin wrinkle and enhancing elasticity
JPH04282321A (en) Cosmetic
KR20080093500A (en) Roe deer urine extract
KR101587077B1 (en) Composition containing fermentated opuntia humifusa showing biological activity of skin
KR20170089093A (en) A cosmetic composition for antioxidating comprising extracts of eisenia bycyclis, gallnut and rhubarb
KR101775485B1 (en) Cosmetic composition containing fermentative extract of Spatholobus suberectus Dunn as active ingredient
KR102240480B1 (en) An anti-acne composition comprising dryopteris erythrosora extracts as an active ingredient
KR101248548B1 (en) Salvia plebeia extract, flavanone compound and Method for manufacturing the same, Cosmetic composition produced therefrom
JPH04282320A (en) Cosmetic
KR102525091B1 (en) A cosmetic compositon for pore-minimizing comprising natural complex extract as an active ingredient
KR102335682B1 (en) Cosmetic Composition For Moisturizing Skin Comprising Fermentative Extract of Equisetum giganteum
KR102814373B1 (en) Cosmetic composition for antioxidant or whitening containing Eckmaxol as an active ingredient
KR101786606B1 (en) cosmetics containing tetrandrine

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

FPAY Annual fee payment

Payment date: 20170626

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20180409

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190520

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

L13-X000 Limitation or reissue of ip right requested

St.27 status event code: A-2-3-L10-L13-lim-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

L13-X000 Limitation or reissue of ip right requested

St.27 status event code: A-2-3-L10-L13-lim-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000